Passer au contenu principal

Frédérick Antoine Mallette

Mallette, Frédérick Antoine

Associate Professor

Affiliation

Université de Montréal

Research Axes

Immunology-oncology

Contact information

Phone: 514-252-3400 , poste3341

fa.mallette@umontreal.ca

Team

  • Béatrice Assaf
  • Karine Boulay
  • Cyril Carvalho
  • Florence Couteau
  • Marzieh Eskandari Shahraki
  • Erlinda Fernandez Diaz
  • Dagmar Glatz
  • Paul Lemire
  • Rana Rizk
  • Tabitha Rosembert
  • Samin Sabouhi Zarafshan
  • Christina Sawchyn
  • Mathieu Neault

Frédérick Antoine Mallette, PhD, heads the Chromatin Structure and Cellular Senescence Research Unit. He is also an associate professor in the Department of Biochemistry and Molecular Medicine at Université de Montréal and the Canada Research Chair in Epigenetics of Aging and Cancer (Tier 2)

The research of Frédérick Antoine Mallette and his team aim to elucidate the molecular mechanisms of cancer formation to identify new pathways that limit tumour progression. The team is interested in senescence (a form of premature cell aging), which provides significant anti-tumour protection. The team also studies genetic defects that inactivate the cell's natural cancer defence mechanisms. In 2016, Frédérick Antoine Mallette and his colleague Marc-Étienne Huot from Université Laval published a study in the prestigious scientific journal Nature Communications. The findings from this study have led to a better understanding of the molecular causes of brain cancer and leukemia and opened the door to more effective personalized chemotherapy.

Research Unit

Chromatin Structure and Cellular Senescence

Research interests

  • Investigate the role of lysine methylation in senescence and cancer by studying the JUMONJI family of lysine demethylases.
  • The regulatory mechanisms of lysine demethylases as well as the biological role of demethylation during different cellular processes including proliferation, transcriptional regulation, the DNA damage response, and tumorigenesis.
  • Identify new therapeutic targets to treat cancer. To achieve this goal, the laboratory integrates different systems and approaches [in genomics (ChIP-chip, ChIP-seq, RNA-seq and microarray chips), proteomics (MS/MS), cytology (fluorescent microscopy, immunohistochemical markers), and genetics (cell and mouse lines)] to elucidate the role of demethylases in different biological pathways.
  • Analyze the effects of the deregulated expression of demethylases on heterochromatin formation during oncogene-induced senescence (a tumour suppression mechanism).
  • Determine the signalling pathways regulated by demethylases and their role in cell transformation.
  • M Gagné, L., Boulay K., Topisirovic I., Huot M.-E.*, Mallette F.A.* (2017) * Equal contribution. Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. Trends in Cell Biology. 27, 738-752.
    More detail
  • Oubaha M., Miloudi K., Dejda A., Guber V., Mawambo G., Germain M.-A., Bourdel G., Popovic N., Rezende F., Kaufman R.J., Mallette F.A.*, Sapieha P.*. (2016) * Contribution égale. Therapeutic inhibition of the senescence-associated secretory phenotype prevents pathological retinal angiogenesis. Science Translational Medicine, 8, 362ra144.
  • Fernandez E. and Mallette FA. (2016) The rise of FXR1 : escaping cellular senescence in heand and neck squamous cell carcinoma. PLoS Genetics, 12, e1006344.
    More detail
  • Carbonneau M, M Gagné L, Lalonde ME, Germain MA, Motorina A, Guiot MC, Secco B, Vincent EE, Tumber A, Hulea L, Bergeman J, Oppermann U, Jones RG, Laplante M, Topisirovic I, Petrecca K, Huot MÉ*, Mallette FA*. (2016) The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nature Communications, 7, 12700. * Contribution égale.
    More detail
  • Neault, M., Mallette, F.A.*, and Richard, S.* (2016) miR-137 modulates a tumor suppressor network-inducing senescence in pancreatic cancer cells. Cell Reports, 14, 1966-78. * Contribution égale.
    More detail
  • Deschenes-Simard, X., Gaumont-Leclerc, M.F., Bourdeau, V., Lessard, F., Moiseeva, O., Forest, V., Igelmann, S., Mallette, F.A., Saba-El-Leil, M.K., Meloche, S., Mes-Masson, A.M., and Ferbeyre, G. (2013) Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev, 27, 900-915.
    More detail
  • Neault, M.*, Mallette, F.A.*, Vogel, G., Michaud-Levesque, J. and Richard, S. (2012) Ablation of PRMT6 reveals a role as a negative transcriptional regulator of the p53 tumor suppressor. Nucleic Acids Res, 40, 9513-21. * contribution égale.
    More detail
  • Mallette, F.A. and Richard, S. (2012) JMJD2A Promotes Cellular Transformation by Blocking Cellular Senescence through Transcriptional Repression of the Tumor Suppressor CHD5. Cell Reports, 2, 1233-1243.
    More detail
  • Mallette, F.A., Mattiroli, F., Cui, G., Young, L.C., Hendzel, M.J., Mer, G., Sixma, T.K. and Richard, S. (2012) RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J, 31, 1865-1878.
    More detail
  • Mallette, F.A., Gaumont-Leclerc, M.F. and Ferbeyre, G. (2007) The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev, 21, 43-48.
    More detail

Education

  • Postdoctoral fellowship

    Lady Davis Institute for Medical Research and the Segal Cancer Proteomics Centre, McGill University

  • PhD

    Université de Montréal

Awards

  • 2016 Canada Research Chair in Epigenetics of Aging and Cancer  (Canadian Institutes of Health Research / CRC))
  • 2013 Junior 1 Research Scholar  (FRQS)
  • 2009 Postdoctoral fellowship  (Canadian Institutes of Health Research)
  • 2008 Postdoctoral fellowship  (National Cancer Institute of Canada / Terry Fox Foundation)
  • 2007 Postdoctoral fellowship  (FRQS)